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Spleen sizing by ultrasound scan and risk of pneumococcal infection
in patients with chronic GVHD: preliminary observations
M Picardi, C Selleri and B Rotoli
Division of Hematology, Federico II University Medical School, Naples, Italy
Summary:
Encapsulated bacteria infections (EBI) can cause severe
complications after BMT, usually occurring in patients
with chronic GVHD (cGVHD) and attributed to func-
tional hyposplenism. Using ultrasound (US) scan, we
measured spleen size in 22 patients transplanted from
HLA identical siblings, with or without cGVHD. No
patient had received TBI, spleen irradiation or penicil-
lin prophylaxis. Results were correlated with occur-
rence of EBI during a mean follow-up of 55 months
(range 7–93). In the group without cGVHD, the differ-
ence between pre- and post-BMT spleen longitudinal
diameters was not significant, and no patient developed
EBI. In the cGVHD group, post-BMT spleen longitudi-
nal diameters were significantly smaller than those pre-
BMT (9.1 – 1.6 vs 12.3 – 2.2; P = 0.0005). Out of four
patients with cGVHD who showed a major spleen size
reduction, two developed a severe infection (an over-
whelming sepsis and a pneumococcal meningitis). In our
small series, we found a borderline relationship between
spleen size reduction and duration of cGVHD (P = 0.06),
as well as an increased risk of life-threatening infection
in patients with extensive cGVHD and hyposplenism as
detected by US scan. We conclude that US scan may be
useful to detect spleen size reduction following allo-
geneic BMT and that penicillin prophylaxis is to be
strongly recommended in patients with extensive
cGVHD and spleen size reduction, even in those who
have not received total body or spleen irradiation.
Keywords: ultrasound scan; hyposplenism; encapsulated
bacteria infection; Streptococcus pneumoniae; chronic
GVHD
Chronic GVHD (cGVHD) is a frequent complication of
allogeneic BMT, and may have serious clinical impli-
cations. About one-half of patients undergoing BMT from
an HLA-matched sibling develop cGVHD, which may
affect various body sites.1,2 cGVHD and subsequent
immunosuppressive treatment may induce increased sus-
ceptibility to pneumococcal and other encapsulated bac-
terial infections (EBI),1,3–6 for which long-term or life-long
penicillin V (or other oral B-lactams) prophylaxis have
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been recommended.3,7 However, the emergence of penicil-
lin-resistant pneumococcal infections is a wordwide prob-
lem8,9 occurring in both immunocompetent10,11 and
immunocompromised12 patients. Since prolonged treatment
with oral B-lactams may favor antibiotic resistance13–15 and
may produce side-effects such as diarrhea, colitis and
pseudo-membranous colitis,16 prudent and proper use of
oral penicillin is suggested.
Although several factors may contribute to immune
response failure after sibling transplant17,18 the spleen
seems to be a key element in host defence against encapsu-
lated bacteria;11 post-BMT functional hyposplenism, attri-
buted to the TBI regimen, has already been documented.19
In this study we used ultrasound (US) scan to evaluate
spleen size in bone marrow transplant patients and corre-
lated spleen size with the occurrence of cGVHD and of
EBI.
Patients and methods
From October 1991 to November 1998, we studied 22
unselected adult patients who had undergone BMT from an
HLA-identical sibling for hematological malignancies and
survived more than 6 months. About one-half of them
presented with cGVHD, histologically documented and
classified according to established criteria.20 Patient charac-
teristics are shown in Tables 1 and 2. All patients were
given Bu-Cy as conditioning, except patients 11, 19 and
22, who received respectively Cy only, Cy-Thiotepa and
Bu-Cy-Melphalan; all had CsA plus short course MTX as
acute GVHD prophylaxis; none had TBI or spleen
irradiation and none received penicillin prophylaxis in the
post-BMT period. All spleen US scans were performed by
the same operator, a hematologist trained in medical ultra-
sonography, using a portable Hitachi (Tokyo, Japan) instru-
ment with a 3.5 MHz probe. The spleen was scanned in
the longitudinal and transverse planes, with the subject in
the supine position, until complete visualization of the
organ was achieved.21 Longitudinal and diagonal diameters
(defined as the maximum length and width, measured with
splenic borders and angles clearly defined) were measured
and the perimeter was marked on the scan, so that the area
was automatically calculated. Reference values were
obtained from 10 age-matched normal subjects. In both
groups of patients (with or without cGVHD), pre-BMT US
spleen size (only longitudinal diameters were available)
was compared with post-BMT size. Univariate analysis of
quantitative variables was performed using Student’s t-test.
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Table 1 Details of transplanted patients without chronic GVHD
Pt. Sex, age Basic disease Splenic size by US scan Encaps. bact. infection Outcome
(years) pre-BMT post-BMT (mo. from BMT)
long long diag areaa
1 F, 31 CML 10.5 9.1 3.5 25 none A&W + 91
2 M, 24 AML 10 10.5 3 27 none A&W + 89
3 F, 43 CML 9.5 11.2 4 41.4 none A&W + 87
4 F, 32 CML 15 11.7 3.4 35 none A&W + 84
5 F, 21 AML 9 11.7 3.4 40.4 none A&W + 83
6 F, 23 AML 9.5 12.5 4.4 39 none A&W + 78
7 M, 47 AML 12 12.5 3.9 44 none A&W + 43
8 M, 45 AML 10 9.2 3 20 none A&W + 39
9 F, 25 CML 10 10 4.3 38 none A&W + 10
10 M, 34 CML 15 11 3.7 40 none A&W + 10
US = ultrasound; long = longitudinal diameter, cm; diag = diagonal diameter, cm; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia;
CML = chronic myeloid leukemia.
aAutomatically calculated from the longest spleen perimeter in cm2.
Finally, we evaluated the incidence of EBI in all patients,
as proved by positive cultures or by typical clinical find-
ings, over a mean follow-up of 55 months (range 7–93).
Results
All US examinations were informative, accurately detecting
spleen size (Tables 1 and 2). In the group of patients with-
out cGVHD, there was no significant difference between
pre- and post-BMT longitudinal diameters, nor between
post-BMT spleen size and those of the control group. In
the cGVHD group, post-BMT longitudinal diameters were
significantly smaller than those pre-BMT (P = 0.0005).
Post-BMT longitudinal diameters and areas were signifi-
cantly smaller than those in the group without cGVHD and
those of the control group. In particular, four patients with
cGVHD (cases 14, 15, 18 and 19) had a post-BMT spleen
size far below the mean normal value. Diagonal diameters
were not significantly different among the three groups
(Table 3).
Spleen size reduction was present in patients with both
limited and extensive cGVHD, and with both short and
long duration of cGVHD. While no relationship was found
between size reduction and severity of the cGVHD
(P = 0.67), a borderline correlation was present with the
duration of cGVHD (P = 0.06). Two patients developed a
life-threatening infection; both had the smallest US spleen
size (Figure 1) and had extensive cGVHD. Patient 14
developed a rapidly fatal septic fever with disseminated
intravascular coagulation and multiorgan failure, which was
suggestive of pneumococcal infection. Patient 18 had
pneumococcal meningitis proven by CSF culture, which
responded to penicillin.
Discussion
Our data show that transplant patients suffering from
cGVHD may develop significant spleen size reduction
which may lead to life-threatening infections, even in the
absence of total body or spleen irradiation. We could not
find a statistically significant relationship between spleen
size reduction and severity of cGVHD, while a weak corre-
lation emerged between size reduction and cGVHD dur-
ation. Moreover, patients who developed a life-threatening
infection had the smallest spleen size and extensive
cGVHD. The mechanism(s) by which the splenic tissue is
reduced in patients with cGVHD remains a matter of specu-
lation. We were able to exclude a role for radiation during
conditioning, since none of our patients had received radi-
ation. It is also unlikely that the cause is graft-induced dam-
age of the splenic lymphoid tissue, since after immunolog-
ical reconstitution most of this should be of donor origin.
Possible explanations are graft-induced damage of host-
derived accessory or stromal cells, or atrophy of the lymph-
oid splenic tissue due to the treatment of cGVHD. Hypo-
splenism is described in other immune-mediated diseases,
such as coeliac disease22 and inflammatory bowel disease.23
The shrinking of splenic tissue is also reminiscent of the
immune-mediated pancreatic tissue hypotrophy that can be
detected by US scan in diabetic patients.24
To the best of our knowledge, this is the first report that
has employed US scanning to investigate spleen size in
allograft patients. Compared to radionuclide techniques, US
scan is a non-invasive, inexpensive, fast and easy tool for
measuring spleen dimensions.25 However, we concede that
US assessment of hyposplenism is only partially reliable:
longitudinal diameter may not represent the real volume
of the organ,21 and linear diameters may not correspond
accurately to the area.
In conclusion, sequential spleen measurements by US in
patients with cGVHD can help to distinguish patients with
a higher risk of pneumococcal infection, and thus needing
long-term antibiotic prophylaxis. Our current policy is to
strongly recommend penicillin V prophylaxis in the patient
subset with US splenic size reduction and extensive
cGVHD. A study of larger cohorts of patients is needed in









Table 2 Details of transplanted patients with chronic GVHD
Pt Sex, age Basic disease Chronic GVHD Splenic size by US scan Encaps. bact. infection Outcome
(years) (mo. from BMT)
Grade Duration Treatment pre-BMT post-BMT
(months)
long long diag areaa
11 F, 30 SAA extensive 89 CsA+Prd, Az 12 9 2.8 28.4 none A&W + 93
12 M, 25 CML extensive 43 CsA+Prd 10.5 10.5 3.8 34.8 none A&W + 68
13 M, 42 AML extensive 56 Az 12 12 4.5 42.5 none A&W + 66
14 F, 31 CML extensive 60 CsA+Prd,Az 18 7 2.5 13 septic shock likely by SP died of fulminant sepsis
61
15 F, 49 AML limited 40 CsA+Prd 10 7.5 4.4 26 none A&W + 60
16 M, 41 CML extensive 27 CsA+Prd, Az 12.4 10 4.1 34.4 none A&W + 58
17 M, 25 HD extensive 16 Prd 13 9.2 2.5 21.1 none A&W + 36
18 M, 39 AML extensive 15 CsA+Prd, Az 11 7.1 2.6 17.8 meningitis by SP died of leukemia relapse
35
19 F, 18 ABL limited 14 CsA+Prd 10 7.5 2.5 14 none A&W + 35
20 F, 22 CML limited 13 Az 15 10.5 3.5 29.7 none A&W + 34
21 M, 38 AML limited 12 CsA+Prd 12 10 3.5 30.7 none A&W + 30
22 F, 30 ABL limited 12 none 12 8.6 3.5 24.5 none A&W + 30
US = ultrasound; long = longitudinal diameter, cm; diag = diagonal diameter, cm; ABL = acute biphenotypic leukemia; CML = chronic myeloid leukemia; HD = Hodgkin’s disease; SAA = severe
aplastic anaemia; AML = acute myeloid leukemia; CsA = cyclosporin A; Prd = prednisone; Az = azathioprine; SP = Streptococcus pneumoniae.
aAutomatically calculated from the longest spleen perimeter in cm2.
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Table 3 Spleen size comparison between normal subjects and post-BMT patient groups
Group Longitudinal Diagonal Area
cm – s.d. P cm – s.d. P cm2 – s.d. P
Controla 10.63 – 0.8
ßøœ 0.52 3.79 – 0.39 ßøœ 0.52 33.05 – 4.6 ßøœ 0.52
cGVHD absent 10.94 – 1.22
ß
ø
œ 0.01 3.7 – 0.5
ß
ø




cGVHD present 9.06 – 1.6 ßøœ 0.006 3.35 – 0.75 ßøœ 0.27 26.4 – 8.87 ßøœ 0.02
aTen age-matched normal subjects.
Bold, statistically significant difference.
Figure 1 Ultrasound spleen size of two patients with cGVHD (b and d: cases 14 and 18) compared with that of sex- and age-matched transplanted
patients without cGVHD (a and c).
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